Compare YieldMax MSTR Option Income Strategy ETF (MSTY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

YieldMax MSTR Option Income Strategy ETFTrade

Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

YieldMax MSTR Option Income Strategy ETF vs Regeneron Pharmaceuticals Inc — how do they compare? YieldMax MSTR Option Income Strategy ETF trades at $13.52, while Regeneron Pharmaceuticals Inc trades at $673.67 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

	MSTY	REGN
Sector	Income / Options Overlay	Health
52-Week High	$108.80	$812.27
52-Week Low	$11.55	$545.46
Market Cap	—	$70.47B
Enterprise Value	—	$64.42B
Dividend Yield	—	0.56%

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MSTY

View details →

REGN

Telix reports Q2 revenue of $247M, strong growth, and advances in cancer therapy trials.GlobeNewsWire · 1 day agoBullish Lawsuit alleges Regeneron misled investors on drug trial results, causing stock to drop sharply.GlobeNewsWire · 4 days agoBearish Class action lawsuit filed against Regeneron over misleading trial results and stock price drop.GlobeNewsWire · 4 days agoBearish View details →

About YieldMax MSTR Option Income Strategy ETF

MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases